Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

Study Status

Open to Enrollment

Study Description

This clinical research trial is for men and women with some form of epithelial cancer. Standard treatments for epithelial cancers involving the stomach, ovaries, pancreas, large intestines and rectum, lung, breast, prostate and liver may use forms of chemotherapy. In some cases, external radiation may also be used. These treatments may slow the cancer for some people, but the cancer will continue to progress in many people.

This research study is evaluating a new, experimental therapy called IMMU-132. IMU-132 is composed of a drug attached to an antibody. The drug is the active ingredient irinotecan, which has shown activity in epithelial cancers. Antibodies are proteins that bind to substances that don’t belong in the body. The antibody used in this study was designed to bind to epithelial cancer tumors.

The purpose of the study is to evaluate the safety of IMU-132 at different dose levels. The study will also investigate the effects of IMMU-132 on advanced epithelial cancer.

Study participants will receive IMU-132 via infusion in 3-week treatment cycles: treatment once a week for 2 consecutive weeks with a 1 week rest period. If the drug is tolerated well without major side effects, participants will repeat the treatment schedule for up to 8 cycles, or 24 weeks. After completing the last dose of IMMU-132, participants will be followed every 3 months for up to 2 years.

Disease Status and/or Stage

Metastatic Epithelial Cancer

Sponsor

Immunomedics

Key Eligibility

  • Men and women, age 18 and older
  • Diagnosed with epithelial cancer of one of the following types:
    • Colorectal cancer
    • Gastric cancer
    • Hepatocellular (liver) cancer
    • Non-small cell lung cancer
    • Ovarian epithelial cancer
    • Triple-negative breast cancer
    • Hormone-refractory prostate cancer
    • Pancreatic ductal adenocarcinoma (pancreatic cancer)
  • Stage IV (metastatic disease)
  • Refractory to or relapsed after at least 1 prior standard therapeutic regimen
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Allyson Ocean, MD

Contact


Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please e-mail:
Erica Bersin
Manager, Subject Recruitment & Communications
(646) 962-8232
erb3001@med.cornell.edu
http://jcto.weill.cornell.edu

Top of page